Floatz logo

EVUZAMITIDE

Transthyretin Amyloidosis

Columbia Universityprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Transthyretin Amyloidosis cohort.

Asset / SponsorPhaseRating
Patisiran
Austin Neuromuscular Center
Phase 3BBB
fx-1006a
Peking University Third Hospital
Phase 4BB
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3BB
Aln-Ttrsc02
Alnylam Pharmaceuticals
Phase 3BB
Doxycycline
Umeå University
Phase 2B

View all 10 →

Same molecule, other indications

EVUZAMITIDE is also rated in:

Cardiac AmyloidosisDormant
BB
Indicative ·
69 / 100
View asset →
amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
primary systemic amyloidosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →